步长制药：公司的注射用艾帕依泊汀α为治疗用生物制品Ⅰ类新药，目前国内尚无同类品种批准上市

Group 1 - The core viewpoint of the article is that the company, Bichang Pharmaceutical, is developing an injectable form of Epaipobatin α, which is a Class I new drug for therapeutic biological products, and currently, there are no similar products approved for sale in the domestic market [2] Group 2 - The company responded to investor inquiries regarding the competitive advantages of its injectable Epaipobatin α compared to existing similar drugs, emphasizing that it holds a unique position in the market due to the absence of comparable products [2]